India's Piramal buys Bayer's potential Alzheimer drug
April 16 (Reuters) - Indian drugmaker Piramal Healthcare has agreed to buy a research and development portfolio from Bayer AG, the company said, in a deal that gives Piramal rights to florbetaben, a possible Alzheimer treatment.
Florbetaben, which is in the final stages of clinical trials, works by detecting symptoms in probable sufferers of Alzheimer's, and is expected to allow earlier detection and specific treatment of the disease, Piramal said in a statement.
Florbetaben is racing with similar Alzheimer's imaging agents from global pharmaceutical companies such as Eli Lilly and Co, Pfizer Inc and General Electric Co to enter a global market estimated at anywhere from $1 billion to $5 billion.
Piramal will acquire intellectual property, worldwide development, marketing and distribution rights of florbetaben and other clinical and pre-clinical assets of Bayer's molecular imaging business in the deal. Financial aspects of the deal were not available.
"We plan to build a promising portfolio in the pharma space, including our newly acquired molecular imaging assets, which will help us create a global branded pharma business," Ajay Piramal, chairman of the Piramal Group, was quoted as saying.
- Tweet this
- Share this
- Digg this
- Rapper Lecrae leads debut-filled top ten of Billboard 200 chart
- UPDATE 2-U.S. House passes bill to avert govt shutdown, extend Export-Import bank
- Biden apologizes for 'Shylocks' gaffe, visits Iowa
- HIGHLIGHTS - Fed chief Yellen's remarks at press conference
- US STOCKS-Wall St edges higher after Fed; Dow sets record
The Federal Reserve renewed its pledge to keep interest rates near zero for a "considerable time," but also indicated it could raise borrowing costs faster than expected when it starts moving. Article | Factbox
China cenbank injects $81 bln into major banks to support economy - reports Full Article